ELI LILLY AND COMPANY

NYSE: LLY (Eli Lilly and Company)

Last update: 6 hours ago

817.34

4.99 (0.61%)

  • 1D 0.61%
  • 5D -3.36%
  • 1M 9.24%
  • 6M 7.95%
  • YTD 5.05%
  • 1Y -10.51%
  • 5Y 456.85%
Previous Close 812.35
Open 812.50
Volume 203,803
Avg. Volume (3M) 4,634,945
Market Cap 732,708,536,320
Price / Earnings (TTM) 53.53
Price / Earnings (Forward) 27.17
Price / Sales 13.89
Price / Book 40.22
52 Weeks Range
623.78 (-23%) — 935.63 (14%)
Earnings Date 30 Oct 2025
TTM Dividend Yield 0.34%
Profit Margin 22.67%
Operating Margin (TTM) 42.49%
Diluted EPS (TTM) 12.27
Quarterly Revenue Growth (YOY) 45.20%
Quarterly Earnings Growth (YOY) 23.00%
Total Debt/Equity (MRQ) 243.61%
Current Ratio (MRQ) 1.37
Operating Cash Flow (TTM) 9.32 B
Levered Free Cash Flow (TTM) -1.82 B
Return on Assets (TTM) 16.45%
Return on Equity (TTM) 77.28%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Bearish
Drug Manufacturers - General (Global) Bullish Bearish
Stock Eli Lilly and Company Bullish Bearish

AIStockmoo Score

0.4
Analyst Consensus 1.5
Insider Activity -3.5
Price Volatility 2.0
Technical Moving Averages 0.0
Technical Oscillators 2.0
Average 0.40

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
LLY 733 B 0.34% 53.53 40.22
NVO 241 B 1.98% 14.12 9.88
NVS 245 B 3.27% 18.46 6.04
MRK 214 B 1.89% 13.20 4.56
JNJ 461 B 1.30% 18.52 5.85
ABBV 407 B 2.10% 109.67 50.46

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Growth
% Held by Insiders 0.16%
% Held by Institutions 83.96%

Ownership

Name Date Shares Held
Lilly Endowment Inc 30 Jun 2025 96,016,978
Pnc Financial Services Group, Inc. 30 Jun 2025 51,293,980
52 Weeks Range
623.78 (-23%) — 935.63 (14%)
Price Target Range
700.00 (-14%) — 1,050.00 (-99%)
High 1,050.00 (JP Morgan, 28.47%) Buy
Median 897.50 (9.81%)
Low 700.00 (HSBC, -14.36%) Hold
Average 896.38 (9.67%)
Total 6 Buy, 2 Hold
Avg. Price @ Call 733.25
Firm Date Target Price Call Price @ Call
Guggenheim 08 Oct 2025 948.00 (15.99%) Buy 845.72
13 Aug 2025 875.00 (7.05%) Buy 660.49
Morgan Stanley 03 Oct 2025 1,023.00 (25.16%) Buy 839.87
Berenberg 17 Sep 2025 830.00 (1.55%) Hold 760.13
JP Morgan 16 Sep 2025 1,050.00 (28.47%) Buy 764.71
HSBC 27 Aug 2025 700.00 (-14.36%) Hold 734.17
Cantor Fitzgerald 13 Aug 2025 825.00 (0.94%) Buy 660.49
Deutsche Bank 11 Aug 2025 900.00 (10.11%) Buy 635.22
UBS 08 Aug 2025 895.00 (9.50%) Buy 625.65
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
LILLY ENDOWMENT INC - 837.54 -956,015 -797,295,082
Aggregate Net Quantity -956,015
Aggregate Net Value ($) -797,295,082
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 837.54
Name Holder Date Type Quantity Price Value ($)
LILLY ENDOWMENT INC 09 Oct 2025 Sell (-) 10,602 855.35 9,068,421
LILLY ENDOWMENT INC 08 Oct 2025 Sell (-) 101,420 845.72 85,772,922
LILLY ENDOWMENT INC 07 Oct 2025 Sell (-) 26,795 843.63 22,605,066
LILLY ENDOWMENT INC 06 Oct 2025 Sell (-) 161,183 845.05 136,207,694
LILLY ENDOWMENT INC 03 Oct 2025 Sell (-) 192,404 839.87 161,594,347
LILLY ENDOWMENT INC 02 Oct 2025 Sell (-) 112,596 819.85 92,311,831
LILLY ENDOWMENT INC 01 Oct 2025 Sell (-) 135,193 825.42 111,591,006
LILLY ENDOWMENT INC 01 Oct 2025 Sell (-) 215,822 825.42 178,143,795
  • 3M
Date Type Details
15 Oct 2025 Announcement Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
13 Oct 2025 Announcement Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
07 Oct 2025 Announcement Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
26 Sep 2025 Announcement Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem
25 Sep 2025 Announcement U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
25 Sep 2025 Announcement Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
23 Sep 2025 CNBC Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs
23 Sep 2025 Announcement Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
22 Sep 2025 CNBC Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera
17 Sep 2025 CNBC Eli Lilly pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial
17 Sep 2025 Announcement Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
17 Sep 2025 Announcement Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
16 Sep 2025 Announcement Lilly announces plans to build $5 billion manufacturing facility in Virginia
16 Sep 2025 CNBC Eli Lilly to build $5 billion Virginia facility to boost production of targeted cancer drugs, other treatments
16 Sep 2025 Announcement Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine
12 Sep 2025 CNBC Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground
11 Sep 2025 CNBC Health care inflation rises as patients, employers brace for biggest jump in health spending in 15 years
11 Sep 2025 Announcement Lilly to participate in Bernstein's 2nd Annual Healthcare Forum
09 Sep 2025 Announcement Lilly launches new "Brain Health Matters" campaign in partnership with Julianne Moore, empowering the public to prioritize brain health
09 Sep 2025 Announcement Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment
08 Sep 2025 Announcement Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL
04 Sep 2025 Announcement Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers
03 Sep 2025 Announcement Defiance Launches LLYZ: The First 2X Short ETF for Eli Lilly
27 Aug 2025 Announcement Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy
26 Aug 2025 CNBC Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval
26 Aug 2025 Announcement Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity
25 Aug 2025 Announcement Lilly to participate in Morgan Stanley 23rd Annual Global Healthcare Conference
24 Aug 2025 CNBC Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
22 Aug 2025 Announcement Lilly to participate in Wells Fargo 20th Annual Healthcare Conference
21 Aug 2025 CNBC FDA approves first-ever glucose monitoring system for weight loss from Signos 
20 Aug 2025 Announcement Anne White to Retire as Executive Vice President and President, Lilly Neuroscience
19 Aug 2025 CNBC Viking Therapeutics shares fall 40% on disappointing obesity pill trial data
18 Aug 2025 CNBC Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients
14 Aug 2025 CNBC Eli Lilly hikes price of diabetes drug Mounjaro in UK as Trump pressures pharma to align drug costs
07 Aug 2025 CNBC Eli Lilly shares drop after obesity pill shows modest late-stage trial results
07 Aug 2025 CNBC Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar
07 Aug 2025 Announcement Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
07 Aug 2025 Announcement Lilly reports second-quarter 2025 financial results and raises guidance
05 Aug 2025 CNBC Trump says pharma tariffs could eventually reach up to 250%
31 Jul 2025 CNBC Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
31 Jul 2025 CNBC Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity
31 Jul 2025 Announcement Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
30 Jul 2025 Announcement Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
29 Jul 2025 Announcement Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL
25 Jul 2025 Announcement Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease
25 Jul 2025 Announcement Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
24 Jul 2025 Announcement Lilly and Verve announce expiration of Verve tender offer
24 Jul 2025 Announcement Lilly confirms date and conference call for second-quarter 2025 financial results announcement
21 Jul 2025 CNBC Weight loss drugs could be a gamechanger for women with a common hormonal disorder
Show more
TTM Dividend Yield 0.34%
5Y Average Dividend Yield 1.10%
Payout Ratio 43.94%
Expected Next Dividend Payment Dec 2025
Ex Date Announcement Date Payment Date Details
14 Feb 2025 09 Dec 2024 10 Mar 2025 1.5 Cash
15 Nov 2024 28 Oct 2024 10 Dec 2024 1.3 Cash
15 Aug 2024 24 Jun 2024 10 Sep 2024 1.3 Cash
15 May 2024 06 May 2024 10 Jun 2024 1.3 Cash
14 Feb 2024 08 Dec 2023 08 Mar 2024 1.3 Cash
14 Nov 2023 01 Nov 2023 08 Dec 2023 1.13 Cash
14 Aug 2023 26 Jun 2023 08 Sep 2023 1.13 Cash
12 May 2023 01 May 2023 09 Jun 2023 1.13 Cash
14 Feb 2023 12 Dec 2022 10 Mar 2023 1.13 Cash
14 Nov 2022 17 Oct 2022 09 Dec 2022 0.98 Cash
12 Aug 2022 27 Jun 2022 09 Sep 2022 0.98 Cash
13 May 2022 02 May 2022 10 Jun 2022 0.98 Cash
14 Feb 2022 13 Dec 2021 10 Mar 2022 0.98 Cash
12 Nov 2021 18 Oct 2021 10 Dec 2021 0.85 Cash
12 Aug 2021 29 Jun 2021 10 Sep 2021 0.85 Cash
13 May 2021 03 May 2021 10 Jun 2021 0.85 Cash
11 Feb 2021 14 Dec 2020 10 Mar 2021 0.85 Cash
12 Nov 2020 19 Oct 2020 10 Dec 2020 0.74 Cash
13 Aug 2020 15 Jul 2020 10 Sep 2020 0.74 Cash
14 May 2020 04 May 2020 10 Jun 2020 0.74 Cash
13 Feb 2020 16 Dec 2019 10 Mar 2020 0.74 Cash
14 Nov 2019 22 Oct 2019 10 Dec 2019 0.645 Cash
14 Aug 2019 20 Jun 2019 10 Sep 2019 0.645 Cash
16 May 2019 07 May 2019 10 Jun 2019 0.645 Cash
14 Feb 2019 19 Dec 2018 08 Mar 2019 0.645 Cash
14 Nov 2018 16 Oct 2018 10 Dec 2018 0.5625 Cash
14 Aug 2018 19 Jun 2018 10 Sep 2018 0.5625 Cash
16 May 2018 07 May 2018 08 Jun 2018 0.5625 Cash
14 Feb 2018 11 Dec 2017 09 Mar 2018 0.5625 Cash
14 Nov 2017 16 Oct 2017 08 Dec 2017 0.52 Cash
11 Aug 2017 19 Jun 2017 08 Sep 2017 0.52 Cash
11 May 2017 01 May 2017 09 Jun 2017 0.52 Cash
13 Feb 2017 12 Dec 2016 10 Mar 2017 0.52 Cash
10 Nov 2016 17 Oct 2016 09 Dec 2016 0.51 Cash
11 Aug 2016 20 Jun 2016 09 Sep 2016 0.51 Cash
11 May 2016 02 May 2016 10 Jun 2016 0.51 Cash
10 Feb 2016 08 Dec 2015 10 Mar 2016 0.51 Cash
10 Nov 2015 19 Oct 2015 10 Dec 2015 0.5 Cash
12 Aug 2015 15 Jun 2015 10 Sep 2015 0.5 Cash
14 May 2015 04 May 2015 10 Jun 2015 0.5 Cash
11 Feb 2015 15 Dec 2014 10 Mar 2015 0.5 Cash
12 Nov 2014 20 Oct 2014 10 Dec 2014 0.49 Cash
13 Aug 2014 16 Jun 2014 10 Sep 2014 0.49 Cash
13 May 2014 05 May 2014 10 Jun 2014 0.49 Cash
12 Feb 2014 16 Dec 2013 10 Mar 2014 0.49 Cash
13 Nov 2013 21 Oct 2013 10 Dec 2013 0.49 Cash
13 Aug 2013 18 Jun 2013 10 Sep 2013 0.49 Cash
14 May 2013 03 May 2013 10 Jun 2013 0.49 Cash
13 Feb 2013 17 Dec 2012 08 Mar 2013 0.49 Cash
13 Nov 2012 15 Oct 2012 10 Dec 2012 0.49 Cash
13 Aug 2012 19 Jun 2012 10 Sep 2012 0.49 Cash
13 Feb 2012 12 Dec 2011 09 Mar 2012 0.49 Cash
10 Nov 2011 17 Oct 2011 09 Dec 2011 0.49 Cash
11 Aug 2011 20 Jun 2011 09 Sep 2011 0.49 Cash
11 May 2011 18 Apr 2011 10 Jun 2011 0.49 Cash
11 Feb 2011 13 Dec 2010 10 Mar 2011 0.49 Cash
10 Nov 2010 18 Oct 2010 10 Dec 2010 0.49 Cash
11 Aug 2010 21 Jun 2010 10 Sep 2010 0.49 Cash
12 May 2010 19 Apr 2010 10 Jun 2010 0.49 Cash
10 Feb 2010 14 Dec 2009 10 Mar 2010 0.49 Cash
10 Nov 2009 19 Oct 2009 10 Dec 2009 0.49 Cash
12 Aug 2009 22 Jun 2009 10 Sep 2009 0.49 Cash
13 May 2009 20 Apr 2009 10 Jun 2009 0.49 Cash
11 Feb 2009 15 Dec 2008 10 Mar 2009 0.49 Cash
12 Nov 2008 20 Oct 2008 10 Dec 2008 0.47 Cash
13 Aug 2008 20 Jun 2008 10 Sep 2008 0.47 Cash
13 Feb 2008 17 Dec 2007 10 Mar 2008 0.47 Cash
13 Nov 2007 15 Oct 2007 10 Dec 2007 0.425 Cash
13 Aug 2007 21 Jun 2007 10 Sep 2007 0.425 Cash
11 May 2007 16 Apr 2007 08 Jun 2007 0.425 Cash
13 Feb 2007 18 Dec 2006 09 Mar 2007 0.425 Cash
13 Nov 2006 16 Oct 2006 08 Dec 2006 0.4 Cash
11 Aug 2006 26 Jun 2006 08 Sep 2006 0.4 Cash
11 May 2006 24 Apr 2006 09 Jun 2006 0.4 Cash
13 Feb 2006 19 Dec 2005 10 Mar 2006 0.4 Cash
10 Nov 2005 17 Oct 2005 09 Dec 2005 0.38 Cash
11 Aug 2005 24 Jun 2005 09 Sep 2005 0.38 Cash
11 May 2005 18 Apr 2005 10 Jun 2005 0.38 Cash
11 Feb 2005 20 Dec 2004 10 Mar 2005 0.38 Cash
10 Nov 2004 18 Oct 2004 10 Dec 2004 0.355 Cash
11 Aug 2004 28 Jun 2004 10 Sep 2004 0.355 Cash
12 May 2004 19 Apr 2004 10 Jun 2004 0.355 Cash
11 Feb 2004 15 Dec 2003 10 Mar 2004 0.355 Cash
12 Nov 2003 20 Oct 2003 10 Dec 2003 0.335 Cash
13 Aug 2003 23 Jun 2003 10 Sep 2003 0.335 Cash
13 May 2003 28 Apr 2003 10 Jun 2003 0.335 Cash
12 Feb 2003 16 Dec 2002 10 Mar 2003 0.335 Cash
13 Nov 2002 21 Oct 2002 10 Dec 2002 0.31 Cash
13 Aug 2002 24 Jun 2002 10 Sep 2002 0.31 Cash
13 May 2002 15 Apr 2002 10 Jun 2002 0.31 Cash
13 Feb 2002 17 Dec 2001 08 Mar 2002 0.31 Cash
13 Nov 2001 15 Oct 2001 10 Dec 2001 0.28 Cash
13 Aug 2001 25 Jun 2001 10 Sep 2001 0.28 Cash
11 May 2001 16 Apr 2001 11 Jun 2001 0.28 Cash
13 Feb 2001 18 Dec 2000 09 Mar 2001 0.28 Cash
13 Nov 2000 16 Oct 2000 11 Dec 2000 0.26 Cash
11 Aug 2000 26 Jun 2000 11 Sep 2000 0.26 Cash
11 May 2000 17 Apr 2000 09 Jun 2000 0.26 Cash
11 Feb 2000 20 Dec 1999 10 Mar 2000 0.26 Cash
10 Nov 1999 18 Oct 1999 10 Dec 1999 0.23 Cash
11 Aug 1999 19 Jul 1999 10 Sep 1999 0.23 Cash
12 May 1999 19 Apr 1999 10 Jun 1999 0.23 Cash
10 Feb 1999 21 Dec 1998 10 Mar 1999 0.23 Cash
10 Nov 1998 20 Oct 1998 10 Dec 1998 0.2 Cash
12 Aug 1998 20 Jul 1998 10 Sep 1998 0.2 Cash
13 May 1998 20 Apr 1998 10 Jun 1998 0.2 Cash
11 Feb 1998 15 Dec 1997 10 Mar 1998 0.2 Cash
12 Nov 1997 15 Sep 1997 10 Dec 1997 0.2 Cash
13 Aug 1997 21 Jul 1997 10 Sep 1997 0.36 Cash
13 May 1997 21 Apr 1997 10 Jun 1997 0.36 Cash
12 Feb 1997 16 Dec 1996 10 Mar 1997 0.36 Cash
13 Nov 1996 21 Oct 1996 10 Dec 1996 0.3425 Cash
13 Aug 1996 15 Jul 1996 10 Sep 1996 0.3425 Cash
13 May 1996 15 Apr 1996 10 Jun 1996 0.3425 Cash
13 Feb 1996 18 Dec 1995 11 Mar 1996 0.3425 Cash
13 Nov 1995 17 Oct 1995 11 Dec 1995 0.685 Cash
11 Aug 1995 17 Jul 1995 11 Sep 1995 0.645 Cash
09 May 1995 17 Apr 1995 12 Jun 1995 0.645 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 1.50 1 0.18
2024 5.20 4 0.67
2023 4.52 4 0.78
2022 3.92 4 1.07
2021 3.40 4 1.23
2020 2.96 4 1.75
2019 2.58 4 1.96
2018 2.25 4 1.94
2017 2.08 4 2.46
2016 2.04 4 2.77
2015 2.00 4 2.37
2014 1.96 4 2.84
2013 1.96 4 3.84
2012 1.47 3 2.98
2011 1.96 4 4.72
2010 1.96 4 5.59
2009 1.96 4 5.49
2008 1.41 3 3.50
2007 1.70 4 3.18
2006 1.60 4 3.07
2005 1.52 4 2.69
2004 1.42 4 2.50
2003 1.34 4 1.91
2002 1.24 4 1.95
2001 1.12 4 1.43
2000 1.04 4 1.12
1999 0.920 4 1.38
1998 0.800 4 0.90
1997 1.28 4 1.84
1996 1.37 4 3.75
1995 1.98 3 7.02
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria